These results suggest that Capmatinib is a promising treatment option for MET‐ and ETV1/ERG‐expressing prostate cancer patients, with potentially greater sensitivity to TKIs in patients with ETV1 or ERG co‐expression. This evidence concerns the gene MET and prostate carcinoma.